Relevant bibliographies by topics / Dopaminergic neurons - Transplantation

Academic literature on the topic 'Dopaminergic neurons - Transplantation'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Dopaminergic neurons - Transplantation.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Dopaminergic neurons - Transplantation"

1

Breeze, Robert E. "TRANSPLANTATION OF EMBRYONIC DOPAMINERGIC NEURONS." Neurosurgery 49, no. 3 (September 1, 2001): 575–76. http://dx.doi.org/10.1097/00006123-200109000-00006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Breeze, Robert E. "TRANSPLANTATION OF EMBRYONIC DOPAMINERGIC NEURONS." Neurosurgery 49, no. 3 (September 2001): 575–76. http://dx.doi.org/10.1227/00006123-200109000-00006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lindvall, Olle. "Treatment of Parkinson's disease using cell transplantation." Philosophical Transactions of the Royal Society B: Biological Sciences 370, no. 1680 (October 19, 2015): 20140370. http://dx.doi.org/10.1098/rstb.2014.0370.

Full text
Abstract:
The clinical trials with intrastriatal transplantation of human fetal mesencephalic tissue, rich in dopaminergic neurons, in Parkinson's disease (PD) patients show that cell replacement can work and in some cases induce major, long-lasting improvement. However, owing to poor tissue availability, this approach can only be applied in very few patients, and standardization is difficult, leading to wide variation in functional outcome. Stem cells and reprogrammed cells could potentially be used to produce dopaminergic neurons for transplantation. Importantly, dopaminergic neurons of the correct substantia nigra phenotype can now be generated from human embryonic stem cells in large numbers and standardized preparations, and will soon be ready for application in patients. Also, human induced pluripotent stem cell-derived dopaminergic neurons are being considered for clinical translation. Available data justify moving forward in a responsible way with these dopaminergic neurons, which should be tested, using optimal patient selection, cell preparation and transplantation procedures, in controlled clinical studies.
APA, Harvard, Vancouver, ISO, and other styles
4

Xiao, Jia-Jia, Ming Yin, Ze-Jian Wang, and Xiao-Ping Wang. "Transplanted Neural Stem Cells: Playing a Neuroprotective Role by Ceruloplasmin in the Substantia Nigra of PD Model Rats?" Oxidative Medicine and Cellular Longevity 2015 (2015): 1–9. http://dx.doi.org/10.1155/2015/618631.

Full text
Abstract:
Although mounting evidence suggests that ceruloplasmin (CP) deficiency and iron deposition are pivotal factors responsible for exacerbating demise of dopaminergic neurons in the substantia nigra (SN) of the Parkinsonism and neural stem cells (NSCs) are believed to be excellent candidates for compensating the lost dopaminergic neurons, there are few researches to explore the change of CP expression and of iron deposition in the pathological microenvironment of SN after NSCs transplantation and the ability of grafted NSCs to differentiate directionally into dopaminergic neurons under the changed homeostasis. With substantia nigral stereotaxic technique and NSCs transplantation, we found that tyrosine hydroxylase and CP expression decreased and iron deposition increased in the lesioned SN after 6-OHDA administration compared with control, while tyrosine hydroxylase and CP expression increased and iron deposition decreased after NSCs transplantation compared to 6-OHDA administration alone. Only a small number of embedding NSCs are able to differentiate into dopaminergic neurons. These results suggest that grafted NSCs have an influence on improving the content of CP expression, which may play a neuroprotective role by decreasing iron deposition and ameliorating damage of dopaminergic neurons and possibly underline the iron-related common mechanism of Parkinson’s disease and Wilson’s disease.
APA, Harvard, Vancouver, ISO, and other styles
5

Li, Wen, Elisabet Englund, Håkan Widner, Bengt Mattsson, Danielle van Westen, Jimmy Lätt, Stig Rehncrona, et al. "Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain." Proceedings of the National Academy of Sciences 113, no. 23 (May 2, 2016): 6544–49. http://dx.doi.org/10.1073/pnas.1605245113.

Full text
Abstract:
Clinical trials using cells derived from embryonic ventral mesencephalon have shown that transplanted dopaminergic neurons can survive and function in the long term, as demonstrated by in vivo brain imaging using 18F-fluorodopa and 11C-raclopride positron emission tomography. Here we report the postmortem analysis of a patient with Parkinson’s disease who 24 y earlier underwent unilateral transplantation of embryonic dopaminergic neurons in the putamen and subsequently exhibited major motor improvement and recovery of striatal dopaminergic function. Histopathological analysis showed that a dense, near-normal graft-derived dopaminergic reinnervation of the putamen can be maintained for a quarter of a century despite severe host brain pathology and with no evidence of immune response. In addition, ubiquitin- and α-synuclein–positive inclusions were seen, some with the appearance of typical Lewy bodies, in 11–12% of the grafted dopaminergic neurons, reflecting the spread of pathology from the host brain to the transplants. Because the clinical benefits induced by transplantation in this patient were gradually lost after 14 y posttransplantation, our findings provide the first reported evidence, to our knowledge, that even a viable dopaminergic graft giving rise to extensive striatal reinnervation may lose its efficacy if widespread degenerative changes develop in the host brain.
APA, Harvard, Vancouver, ISO, and other styles
6

Petersén, Åsa, Oskar Hansson, Mia Emgård, and Patrik Brundin. "Grafting of Nigral Tissue Hibernated with Tirilazad Mesylate and Glial Cell Line-Derived Neurotrophic Factor." Cell Transplantation 9, no. 5 (September 2000): 577–84. http://dx.doi.org/10.1177/096368970000900503.

Full text
Abstract:
Transplantation of embryonic ventral mesencephalon is a potential therapy for patients with Parkinson's disease. As only around 5–10% of embryonic dopaminergic neurons survive grafting into the adult striatum, it is considered necessary to use multiple donor embryos. To increase the survival of the grafted dopaminergic neurons, the clinical transplantation program in Lund currently employs the lipid peroxidation inhibitor, tirilazad mesylate, in all solutions used during tissue storage, preparation, and transplantation. However, the difficulty in obtaining a sufficient number of donor embryos still remains an important limiting factor for the clinical application of neural transplantation. In many clinical transplantation programs, it would be a great advantage if human nigral donor tissue could be stored for at least 1 week. This study was performed in order to investigate whether storage of embryonic tissue at 4°C for 8 days can be applied clinically without creating a need to increase the number of donors. We compared the survival of freshly grafted rat nigral tissue, prepared according to the clinical protocol, with tissue transplanted after hibernation. Thus, in all groups tirilazad mesylate was omnipresent. One group of rats was implanted with fresh tissue and three groups with hibernated tissue with or without addition of glial cell line-derived neurotrophic factor (GDNF) in the hibernation medium and/or the final cell suspension. Earlier studies have suggested that GDNF improves the survival of hibernated nigral transplants. We found no statistically significant difference between the groups regarding graft survival after 3 weeks. However, there was a nonsignificant trend for fewer surviving dopaminergic neurons in grafts from hibernated tissue compared to fresh controls. Furthermore, we show that the addition of GDNF to the hibernation medium and/or to the final cell suspension does not significantly increase the survival of the dopaminergic neurons.
APA, Harvard, Vancouver, ISO, and other styles
7

Sawamoto, K., N. Nakao, K. Kobayashi, N. Matsushita, H. Takahashi, K. Kakishita, A. Yamamoto, et al. "Visualization, direct isolation, and transplantation of midbrain dopaminergic neurons." Proceedings of the National Academy of Sciences 98, no. 11 (May 15, 2001): 6423–28. http://dx.doi.org/10.1073/pnas.111152398.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Vukicevic, Vladimir, Janine Schmid, Andreas Hermann, Sven Lange, Nan Qin, Linda Gebauer, Kuei-Fang Chung, et al. "Differentiation of Chromaffin Progenitor Cells to Dopaminergic Neurons." Cell Transplantation 21, no. 11 (November 2012): 2471–86. http://dx.doi.org/10.3727/096368912x638874.

Full text
Abstract:
The differentiation of dopamine-producing neurons from chromaffin progenitors might represent a new valuable source for replacement therapies in Parkinson's disease. However, characterization of their differentiation potential is an important prerequisite for efficient engraftment. Based on our previous studies on isolation and characterization of chromaffin progenitors from adult adrenals, this study investigates their potential to produce dopaminergic neurons and means to enhance their dopaminergic differentiation. Chromaffin progenitors grown in sphere culture showed an increased expression of nestin and Mash1, indicating an increase of the progenitor subset. Proneurogenic culture conditions induced the differentiation into neurons positive for neural markers β-III-tubulin, MAP2, and TH accompanied by a decrease of Mash1 and nestin. Furthermore, Notch2 expression decreased concomitantly with a downregulation of downstream effectors Hes1 and Hes5 responsible for self-renewal and proliferation maintenance of progenitor cells. Chromaffin progenitor-derived neurons secreted dopamine upon stimulation by potassium. Strikingly, treatment of differentiating cells with retinoic and ascorbic acid resulted in a twofold increase of dopamine secretion while norepinephrine and epinephrine were decreased. Initiation of dopamine synthesis and neural maturation is controlled by Pitx3 and Nurr1. Both Pitx3 and Nurr1 were identified in differentiating chromaffin progenitors. Along with the gained dopaminergic function, electrophysiology revealed features of mature neurons, such as sodium channels and the capability to fire multiple action potentials. In summary, this study elucidates the capacity of chromaffin progenitor cells to generate functional dopaminergic neurons, indicating their potential use in cell replacement therapies.
APA, Harvard, Vancouver, ISO, and other styles
9

Park, Hyunjun, and Keun-A. Chang. "Therapeutic Potential of Repeated Intravenous Transplantation of Human Adipose-Derived Stem Cells in Subchronic MPTP-Induced Parkinson’s Disease Mouse Model." International Journal of Molecular Sciences 21, no. 21 (October 30, 2020): 8129. http://dx.doi.org/10.3390/ijms21218129.

Full text
Abstract:
Parkinson’s disease (PD) is the second most common neurodegenerative disease, which is clinically and pathologically characterized by motor dysfunction and the loss of dopaminergic neurons in the substantia nigra, respectively. PD treatment with stem cells has long been studied by researchers; however, no adequate treatment strategy has been established. The results of studies so far have suggested that stem cell transplantation can be an effective treatment for PD. However, PD is a progressively deteriorating neurodegenerative disease that requires long-term treatment, and this has been insufficiently studied. Thus, we aimed to investigate the therapeutic potential of human adipose-derived stem cells (hASC) for repeated vein transplantation over long-term in an animal model of PD. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model mice, hASCs were administered on the tail vein six times at two-week intervals. After the last injection of hASCs, motor function significantly improved. The number of dopaminergic neurons present in the nigrostriatal pathway was recovered using hASC transplantation. Moreover, the administration of hASC restored altered dopamine transporter expression and increased neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF), in the striatum. Overall, this study suggests that repeated intravenous transplantation of hASC may exert therapeutic effects on PD by restoring BDNF and GDNF expressions, protecting dopaminergic neurons, and maintaining the nigrostriatal pathway.
APA, Harvard, Vancouver, ISO, and other styles
10

Emgard-Mattson, Mia, Jenny Karlsson, Naoyuki Nakao, and Patrik Brundin. "Addition of Lateral Ganglionic Eminence to Rat Mesencephalic Grafts Affects Fiber Outgrowth but Does not Enhance Function." Cell Transplantation 6, no. 3 (May 1997): 277–86. http://dx.doi.org/10.1177/096368979700600310.

Full text
Abstract:
Addition of embryonic striatal tissue, usually as a combination of the lateral and medial ganglionic eminences, to intrastriatal mesencephalic grafts has previously been reported to enhance recovery of drug-induced rotational behavior in the host and to modify axonal fiber outgrowth from the grafted dopaminergic neurons. This study investigated the effects of adding (cografting) either lateral or medial ganglionic eminence tissue to embryonic mesencephalic grafts implanted intrastriatally, in rats with unilateral 6-hydroxydopamine lesions. The cografts did not exhibit increased survival or cell size of dopaminergic neurons when compared to transplants of mesencephalic tissue alone. Neither did recipients of cografts exhibit any enhancement of graft-induced recovery of function, when tested for drug-induced rotational behavior or forelimb function in the staircase test. However, cografts containing lateral ganglionic eminence displayed patches of dense tyrosine hydroxylase-immunoreactive fibers within the graft tissue. These patches largely coincided with patches in adjacent stained sections, which were rich in immunostaining for the striatal-specific marker dopamine- and cyclic AMP-regulated phosphoprotein-32 (DARPP-32). Such patches were not present in rats receiving cografts containing medial ganglionic eminence or mesencephalic tissue alone. Thus, it seems that the grafted dopaminergic neurons preferentially grow into the areas of the transplants containing lateral ganglionic eminence tissue. In summary, the results suggest that embryonic lateral ganglionic eminence exerts trophic effects on the outgrowth of dopaminergic axons, but does not enhance the behavioral effects of grafted dopaminergic neurons.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Dopaminergic neurons - Transplantation"

1

Zietlow, Rike. "Factors affecting the survival of embryonic dopaminergic neurones after transplantation." Thesis, University of Cambridge, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.624313.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Love, Rebecca Margaret. "Improving the survival of embryonic dopaminergic neurons." Thesis, University of Oxford, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.343277.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Daniel, James St Vincent Clinical School UNSW. "Studies of neurotransmitter release mechanisms in dopamine neurons." Awarded by:University of New South Wales. St. Vincent Clinical School, 2007. http://handle.unsw.edu.au/1959.4/31934.

Full text
Abstract:
Medications that treat diseases such as Parkinson???s disease work by regulating dopamine transmission at synapses. Surprisingly, little is known about the mechanisms regulating dopamine release at synapses. In this thesis, we study mechanisms that regulate vesicle recycling in axons and dendrites of dopamine neurons. Key questions we addressed were: (1) Are vesicles in axons and dendrites associated with the same regulatory proteins, and thus by implication the same regulatory mechanisms, as in excitatory neurons; (2) Do vesicles undergo recycling, and (3) if so, are they characterised by a distinct pool size and rate of recycling. To study this, we cultured dopamine neurons and used immunocytochemistry to detect vesicular monoamine transporter 2 (VMAT2) and identify axons, dendrites and synaptic proteins, combined with labelling of recycling vesicles using FM 1-43. Vesicles in axons, but not in dendrites, were associated with presynaptic proteins such as Synaptophysin and Bassoon. We identified two kinds of presynaptic sites in axons: ???synaptic??? (located close to soma and dendrites??? and ???orphan???. The recycling vesicle pool size was smaller at orphan sites than at synaptic sites, and the initial rate of vesicle pool release was also lower at orphan sites. Both synaptic and orphan sites exhibited lower rates of vesicle pool release compared to hippocampal synapses, suggesting functional differences in presynaptic physiology between dopamine neurons and hippocampal neurons. In somatodendritic regions, VMAT2 was localised to the endoplasmic reticulum, Golgi, endosome, and large dense-core vesicles, suggesting that these vesicles might function as a part of the regulated secretory pathway in mediating dopamine release. None of the synaptic vesicle proteins we studied were detected in these regions, although some preliminary evidence of vesicle turnover was detected using FM 1-43 labelling. This thesis provides a detailed analysis of neurotransmitter release mechanisms in dopamine neurons. Our data suggests that presynaptic release of dopamine is mediated by mechanisms similar to those observed in excitatory neurons. In somatodendritic regions, our data suggests that VMAT2 is localised to organelles in secretory pathways, and that distinct mechanisms of release might be present at somatodendritic sites to those present in presynaptic sites. This thesis provides novel methods for analysing vesicle recycling in dopamine neurons, which provides the basis for further studies examining presynaptic function of dopamine neurons in normal brain function, disease, and therapeutic approaches.
APA, Harvard, Vancouver, ISO, and other styles
4

Samata, Bumpei. "Purification of functional human ES and iPSC-derived midbrain dopaminergic progenitors using LRTM1." 京都大学 (Kyoto University), 2017. http://hdl.handle.net/2433/225509.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Scholz, Torben [Verfasser], and Guido [Akademischer Betreuer] Nikkhah. "Development of dopaminergic neurons from neural stem cells and transplantation into a neonatal and adult animal model of Parkinson’s disease = Entwicklung dopaminerger Neurone aus neuralen Stammzellen und Transplantation in ein neonatales und adultes Modell der Parkinsonschen Krankheit." Freiburg : Universität, 2011. http://d-nb.info/112346460X/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Torikoshi, Sadaharu. "Exercise Promotes Neurite Extensions from Grafted Dopaminergic Neurons in the Direction of the Dorsolateral Striatum in Parkinson’s Disease Model Rats." Doctoral thesis, Kyoto University, 2021. http://hdl.handle.net/2433/263556.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Brisson, Sandie. "Potentiel thérapeutique de neurones dopaminergiques dérivés de cellules souches embryonnaires de souris dans un modèle murin de la maladie de Parkinson." Thesis, Poitiers, 2017. http://www.theses.fr/2017POIT2314.

Full text
Abstract:
La maladie de Parkinson (MP) est caractérisée essentiellement par la perte progressive des neurones dopaminergiques (DA) de la substance noire parse compacte (SNpc) qui innervent le striatum et contrôlent les mouvements volontaires. Une des approches thérapeutiques de la MP est la transplantation ectopique de précurseurs DA fœtaux issus du mésencéphale ventral (MV) dans le striatum. Il est peu probable que la transplantation des neurones DA du MV humain devienne un traitement de routine de la MP en raison de problèmes d’approvisionnement et de standardisation de tissus pour la transplantation. L’avenir de ces greffes dépend donc de l’obtention de sources alternatives de tissus. L’objectif de ce projet est d’obtenir des neurones DA issus de cellules souches embryonnaires de souris et d’évaluer leur potentiel thérapeutique en les greffant dans le striatum ou la SN dans un modèle murin de la MP. Afin d’augmenter le nombre de neurones DA du type nigral, l’expression de LMX1A, un facteur de transcription jouant un rôle clé dans le développement embryonnaire des progéniteurs des neurones DA du MV, a été forcée. Nous avons montré que, in vitro, LMX1A induit une augmentation de précurseurs et de neurones DA du type nigral. Après transplantation dans la SN ou le striatum, les cellules survivent, expriment des marqueurs de neurones DA du type nigral et projettent vers le striatum. L’expression forcée de LMX1A semble augmenter, in vivo, la proportion de neurones DA matures responsables d’une réduction des déficits moteurs après transplantation dans le striatum
Parkinson’s disease (PD) is mainly characterised by the progressive loss of the dopaminergic (DA) neurons of the subtantia nigra pars compacta (SNpc) that are innervating the striatum and controlling voluntary movements. One of the therapeutical strategies of PD is the ectopic transplant of fetal DA precursors from the ventral mesencephalon (VM) into the striatum. It is unlikely that transplant of human DA neurons of the VM become a routine treatment for PD due to supply and tissues standardization problems for the transplant. The future of these transplants thus depends on the obtaining of alternative tissue sources. The aim of this project is to obtain DA neurons derived from mouse embryonic stem cells and to evaluate their therapeutical potential grafting them into the striatum or the SNpc in a mouse model of PD. In order to increase the number of DA neurons of the nigral subtype, the expression of LMX1A, a transcription factor playing a key role in the embryonic development of MV DA neuronal progenitors, was forced. We have shown that, in vitro, LMX1A induces an increase of nigral precursors and neurons. After transplantation into the SN or the striatum, the cells survive, express markers of DA neurons of the nigral subtype and project towards the striatum. The forced expression of LMX1A seems to increase, in vivo, the proportion of mature DA neurons responsible for reducing the motor deficits after transplantation into the striatum
APA, Harvard, Vancouver, ISO, and other styles
8

Thinyane, Keneuoe Hycianth. "Transplantation of mouse embryonic stem cell-derived dopaminergic neurons in a unilateral 6-hydroxydopamine lesion rat model of Parkinson's disease characterisation of the fate of the engrafted cells and the host responses /." [S.l.] : [s.n.], 2004. http://deposit.ddb.de/cgi-bin/dokserv?idn=975112600.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Dong, Jing-fei. "Morphological and biochemical characterization of human second trimester foetal dopaminergic neurones and identification of factors influencing their survival and preservation in vitro : a study related to clinical neural transplantation for Parkinson's d." Thesis, University of Wolverhampton, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.357198.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cheng, Yun-Chih, and 鄭遠芝. "Transplantation of dopaminergic neurons derived from human umbilical mesenchymal stem cells into striatum of hemiparkinsonian rats." Thesis, 2004. http://ndltd.ncl.edu.tw/handle/06771948236164021847.

Full text
Abstract:
碩士
國立陽明大學
解剖暨細胞生物學研究所
92
Transplantation of stem cells has been the foresight to rescue human neurodegenerative diseases in recent years. Embryonic stem cells are pluripotent. Transplantation of embryonic or fetus tissue is hindered by disputations in the aspects of religion, law and ethic, and therefore not available to all. Bone marrow has come into notice. Bone marrow contains heamatopoietic stem cells that provide a continuous source for progenitors of red blood cells, white blood cells and platelets. Moreover, bone marrow also contains nonheamatopoietic stem cells that have been referred to as bone marrow stromal cells or bone marrow mesenchymal stem cells. Bone marrow stromal cells are capable of differentiating into osteogenic, chondrogenic and neurogenic lineages in vitro. However, the number of bone marrow stromal cells significantly decreases with age (Rao and Mattson, 2001). Therefore, it is more urgent to find an alternative source of stem cells. Direct transplantation of stem cells, a relatively low percentage of cells differentiates into neurons with the majority into glia and thus cannot rescue the neurological disease (Azizi et al., 1998 ；McDonald et al.,1999). Therefore, transplantation of postmitosis neurons derived from stem cells has become an effective and direct treatment for the neurological diseases. We have shown a novel source of stem cells from Wharton’s jelly of human umbilical cord. The human umbilical mesenchymal stem cells (HUMSCs) were cultured and differentiated into dopaminergic neurons in vitro, and then transplanted into striatum of hemiparkinsonian rats. Here we showed quantities of HUMSCs that extrated from Wharton’s jelly of human umbilical cord. At the sixth-ninth day of cultured in neuronal condition medium (NCM), the percentage of HUMSCs expressed neurofilament could as high as 87%, and less than 5% of HUMSCs differentiated into astrocytes and microglia. Transplantation of neurons derived from HUMSCs into striatum of hemiparkinsonian rats, the cells survived in striatum after 4 months. However, the rotation behavior of hemiparkinsonian rats was still not improved. Differentiation of HUMSCs into dopaminergic neurons is necessary for success in behavioral recovery of hemiparkinsonian rats. HUMSCs were cultured in NCM for 6 days, and then Shh and FGF8 were added. 12.7% of HUMSCs differentiated into dopaminergic neurons after Shh and FGF8 treatment. The rotation behavior become alleviated, but could not back to normal after transplantation of dopaminergic neurons derived from HUMSCs into striatum of hemiparkinsonian rats. Our results suggest that HUMSCs have great potentialities for differentiation into dopaminergic neurons after Shh and FGF8 treatment. However, the low proportion of dopaminergic neurons generation may not be sufficient to recover from Parkinson’s disease. Now we are excusing a plan to transfect Nurr1 gene into human umbilical mesenchymal stem cells to generate dopaminergic neurons in quantity to rescue Parkinson’s disease efficiently.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Dopaminergic neurons - Transplantation"

1

Triarhou, Lazaros C. Dopaminergic Neuron Transplantation in the Weaver Mouse Model of Parkinson’s Disease. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0699-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dong, Jing-fei. Morphological and biochemical characterization of human second trimester foetal dopaminergic neurones and identification of factors influencing their survival and preservation in vitro: A study related to clinical neural transplantation for Parkinson's disease. Wolverhampton: University of Wolverhampton, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Triarhou, Lazaros C. Dopaminergic Neuron Transplantation in the Weaver Mouse Model of Parkinson's Disease. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dopaminergic Neuron Transplantation in the Weaver Mouse Model of Parkinson's Disease. Springer, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Triarhou, Lazaros C. Dopaminergic Neuron Transplantation in the Weaver Mouse Model of Parkinson's Disease (Advances in Experimental Medicine and Biology, 517). Kluwer Academic/Plenum Publishers, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Dopaminergic neurons - Transplantation"

1

Takahashi, Jun, Yasushi Takagi, and Hidemoto Saiki. "Transplantation of Embryonic Stem Cell-Derived Dopaminergic Neurons in MPTP-Treated Monkeys." In Methods in Molecular Biology, 199–212. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-060-7_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Seiger, Ake, Lars Olson, Ingrid Stromberg, Marc Bygdeman, Menek Goldstein, and Barry Hoffer. "Transplantation of Human Dopaminergic Neurons in Parkinsonism: Experimental Reality and Future Clinical Feasibility." In Progress in Parkinson Research, 219–23. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4613-0759-4_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Triarhou, Lazaros C. "Introduction." In Dopaminergic Neuron Transplantation in the Weaver Mouse Model of Parkinson’s Disease, 1–14. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0699-7_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Triarhou, Lazaros C. "Biology and Pathology of the Weaver Mutant Mouse." In Dopaminergic Neuron Transplantation in the Weaver Mouse Model of Parkinson’s Disease, 15–42. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0699-7_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Triarhou, Lazaros C. "Histochemical Properties of Intrastriatal Mesencephalic Grafts." In Dopaminergic Neuron Transplantation in the Weaver Mouse Model of Parkinson’s Disease, 43–61. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0699-7_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Triarhou, Lazaros C. "Structural Correlates of Process Outgrowth and Circuit Reconstruction." In Dopaminergic Neuron Transplantation in the Weaver Mouse Model of Parkinson’s Disease, 63–88. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0699-7_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Triarhou, Lazaros C. "Neurochemical Indices of Functional Restoration." In Dopaminergic Neuron Transplantation in the Weaver Mouse Model of Parkinson’s Disease, 89–105. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0699-7_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Triarhou, Lazaros C. "Behavioral Recovery of Functional Responses." In Dopaminergic Neuron Transplantation in the Weaver Mouse Model of Parkinson’s Disease, 107–25. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0699-7_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Triarhou, Lazaros C. "Directions for Future Research." In Dopaminergic Neuron Transplantation in the Weaver Mouse Model of Parkinson’s Disease, 127–42. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0699-7_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chung, Sangmi, Jisook Moon, and Kwang-Soo Kim. "Improvement of Neurological Dysfunctions in Aphakia Mice, a Model of Parkinson’s Disease, after Transplantation of ES Cell-Derived Dopaminergic Neuronal Precursors." In Methods in Molecular Biology, 285–91. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1453-1_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Dopaminergic neurons - Transplantation' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography